Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
Jemperli approval now includes MMRp/MSS tumors, which represent majority of endometrial cancer cases.
Download (PDF, 318.6KB) -
GSK and Flagship Pioneering partner to discover novel medicines and vaccines
Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ bioplatform companies
Download (PDF, 130.7KB) -
Statement: Zantac (ranitidine) litigation – Kimbrow case
GSK has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court.
Download (PDF, 110.4KB) -
GSK begins shipping influenza vaccine doses for 2024-25 season
GSK today announced it has started shipping doses of trivalent influenza vaccines to US healthcare providers and pharmacies.
Download (PDF, 230.3KB) -
Statement: US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices updates recommendations on adult RSV vaccines ahead of the next season
GSK today announced that the US CDC ACIP voted in favor of recommending the routine use of RSV vaccines in all adults aged 75 and above.
Download (PDF, 245.2KB) -
Students nationwide take on the role of space scientists during GSK science in the summer™ in collaboration with the Franklin Institute
Students across the US participate in the free GSK Science in the Summer™ program, partnered with The Franklin Institute.
Download (PDF, 336.0KB) -
Statement: Zantac (ranitidine) litigation – GSK starts process for appeal of recent Delaware Daubert decision
GSK confirms that the Company has taken the first step to seek appeal of the recent Daubert ruling, made by the Delaware Superior Court.
Download (PDF, 132.5KB) -
Statement: Zantac (ranitidine) litigation – Kasza case
GSK welcomes the plaintiff’s voluntary dismissal of the next Zantac case (Kasza).
-
US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
GSK announced FDA approval of AREXVY Vaccine to prevent LRTD in adults aged 50-59 at heightened risk.
Download (PDF, 207.2KB) -
GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Download (PDF, 126.4KB) -
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024.
Download (PDF, 272.9KB) -
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement.
-
Statement: Zantac (ranitidine) litigation – Delaware State Court Daubert Ruling
GSK disagrees with ruling by the Delaware State Court and will immediately seek an appeal.
-
New data at ASCO showcases the transformational potential of GSK's oncology portfolio
Pivotal data will be shared from the DREAMM-8 and DREAMM-7 phase III trials.
Download (PDF, 374.8KB) -
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases
Jury in Valadez case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer
-
FDA approves Benlysta (belimumab) Autoinjector for children with systemic lupus erythematosus
FDA approves GSK's 200mg subcutaneous Benlysta for patients five years of age or older. A treatment to inhibit B-lymphocyte stimulator.
Download (PDF, 100.1KB) -
US FDA accepts for priority review GSK’s application for an expanded indication of Jemperli (dostarlimab-gxly) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer
Application supported by statistically significant and clinically meaningful progression-free and overall survival data from RUBY trial
Download (PDF, 189.3KB) -
New long-term data show SHINGRIX continues to provide high protection against shingles in adults aged 50 and over for more than a decade
End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination
Download (PDF, 192.8KB) -
GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Submission based on results from pivotal phase III trial showing all primary endpoints met
Download (PDF, 186.4KB) -
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
ViiV Healthcare announces U.S. FDA approval of Dovato for the treatment of HIV-1 infection in adolescents 12 years of age and older.
Download (PDF, 236.4KB)
